Compare ACAD & ABG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACAD | ABG |
|---|---|---|
| Founded | 1993 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.8B |
| IPO Year | 2000 | 2001 |
| Metric | ACAD | ABG |
|---|---|---|
| Price | $22.18 | $202.14 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 22 | 6 |
| Target Price | $30.55 | ★ $244.33 |
| AVG Volume (30 Days) | ★ 1.4M | 207.1K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.12 | 16.88 |
| EPS | 2.30 | ★ 25.13 |
| Revenue | $726,437,000.00 | ★ $17,999,000,000.00 |
| Revenue This Year | $18.80 | $5.51 |
| Revenue Next Year | $11.70 | $2.53 |
| P/E Ratio | $9.87 | ★ $7.96 |
| Revenue Growth | ★ 40.45 | 4.71 |
| 52 Week Low | $14.20 | $184.61 |
| 52 Week High | $28.35 | $274.50 |
| Indicator | ACAD | ABG |
|---|---|---|
| Relative Strength Index (RSI) | 50.95 | 49.01 |
| Support Level | $21.51 | $187.30 |
| Resistance Level | $22.97 | $255.30 |
| Average True Range (ATR) | 0.66 | 7.42 |
| MACD | 0.08 | -0.08 |
| Stochastic Oscillator | 66.67 | 51.20 |
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
Asbury Automotive Group is a regional collection of automobile dealerships that went public in March 2002. The company operates 171 new-vehicle stores and 39 collision centers. Over 70% of new-vehicle revenue is from luxury and import brands. Asbury also offers third-party financing and insurance products and its own F&I products via Total Care Auto. Asbury operates in 15 states (mostly in Rocky Mountain states, Texas, the Northeast, and Southeast). Asbury store brands include Herb Chambers in the Northeast, McDavid and Park Place in Texas, Koons in the Washington, D.C. area, and the Larry H. Miller brand in the Western US. Asbury generated about $18 billion of revenue in 2025 and is based in the Atlanta area. The firm targets at least $30 billion of revenue sometime around 2030.